Roadzen Inc. (NASDAQ: RDZN) filed an 8-K on Tuesday disclosing it has deferred installment payments on outstanding convertible notes and extended investor financing rights through June 2026. The micro-cap InsurTech platform operator notified noteholders that scheduled payments totaling approximately $2.7 million will be pushed to later dates, while simultaneously granting existing investors extended warrant exercise windows and additional conversion rights.
The deferral covers notes issued between Q4 2023 and Q2 2024 to a consortium that includes institutional crossover funds and family offices with prior exposure to Indian fintech infrastructure. Under the amended terms, Roadzen will defer $1.1 million in principal due March 2025 to September 2025, and another $1.6 million originally due June 2025 to December 2025. In exchange, noteholders received warrant coverage extensions from 24 months to 36 months post-issuance, and the conversion price floor was lowered from $3.20 to $2.40 per share—a 25% haircut reflecting the stock's decline from its April 2024 highs near $4.80 to current levels around $1.90.
This marks Roadzen's third material debt restructuring since October 2023, when it first extended a bridge facility from lead investor Saama Capital. The company operates an AI-driven insurance distribution and underwriting platform across India, the UAE, and pilot markets in Southeast Asia, processing roughly $140 million in annualized gross written premiums as of Q3 2024. Revenue grew 62% year-over-year to $18.3 million in the nine months ended September 2024, but adjusted EBITDA remained negative at -$9.1 million, narrowing only $600,000 from the prior year period. Cash on the balance sheet as of September 30 stood at $4.2 million, against $11.8 million in current liabilities—a working capital deficit the company has managed through sequential note tranches and vendor term extensions.
The extended investor rights include anti-dilution protections and a most-favored-nation clause that automatically adjusts their terms if Roadzen raises capital at more favorable conditions before December 2025. This structure effectively locks the company into maintaining current noteholders' relative positioning or risking a full ratchet reset. Market participants note similar clauses have historically constrained microcap growth companies from accessing opportunistic equity raises during valuation recoveries. Worth noting: Roadzen's float remains thin at roughly 4.1 million shares, with insiders and early backers controlling approximately 71% of the equity, limiting liquidity for new institutional entry even if operations inflect positively.
Allocators should monitor Roadzen's Q4 2024 earnings release expected late February for updated cash burn guidance and any mention of a larger refinancing or strategic partnership. The company has signaled intentions to pursue a Middle Eastern sovereign-adjacent insurance joint venture that could provide non-dilutive capital, with preliminary term sheets expected by March 2025. Separately, watch for any SEC filings related to warrant exercises or note conversions in the 90 days following this amendment—early conversions would indicate noteholders expect near-term value crystallization or prefer equity exposure over extended debt tenor.
Roadzen's Bangalore-based technical team continues to ship product updates and expand API integrations with regional insurers, but the capital structure now compresses optionality until the business either reaches cash-flow breakeven or secures a balance-sheet repair transaction that clears the overhang.